China NMPA Drug Inspection - Yunnan Mingding Pharmaceutical Co., Ltd. - Polyporus umbellatus

The Yunnan Provincial Food and Drug Administration issued an announcement on June 26, 2018, detailing findings from its first-quarter 2018 drug quality supervision and sampling inspections. The inspections aimed to strengthen drug quality oversight and ensure public safety across drug production, operation, and use units within the province. Multiple companies, including Yunnan Xianghui Pharmaceutical Co., Ltd., Dongchuan District Jingtian Traditional Chinese Medicine Slices Factory, Yunnan Jinfeng Pharmaceutical Co., Ltd., and Anhui Meiyu Traditional Chinese Medicine Pieces Co., Ltd., were cited for deficiencies. Main violations involved numerous traditional Chinese medicinal products failing to meet quality standards outlined in the 2010 and 2015 editions of the Chinese Pharmacopoeia. Recurring issues included non-compliance with specified 'Properties' (physical characteristics) and 'Identification' tests, indicating potential problems with drug authenticity or processing. Critical findings also revealed instances where drugs were not produced by the indicated manufacturer, and in one case, a production company (Xuanwei Zhenghe Traditional Chinese Medicine Pieces Co., Ltd.) had dissolved, preventing verification. These issues highlight significant lapses in manufacturing quality control, product traceability, and supply chain integrity, prompting regulatory action through public disclosure to enhance pharmaceutical standards.